P/E ratio for Taro Pharmaceutical (TARO)
P/E ratio as of April 2024 (TTM): 69.2
According to Taro Pharmaceutical's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 69.1639. At the end of 2021 the company had a P/E ratio of > 1000.
P/E ratio history for Taro Pharmaceutical from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | > 1000 | -13596.67% |
| 2020 | -9.28 | -168.19% |
| 2019 | 13.6 | 26.72% |
| 2018 | 10.7 | -47.17% |
| 2017 | 20.3 | 125.78% |
| 2016 | 9.01 | -21.34% |
| 2015 | 11.4 | -23.83% |
| 2014 | 15.0 | 8.81% |
| 2013 | 13.8 | 68.39% |
| 2012 | 8.20 | 14.01% |
| 2011 | 7.20 | -26.01% |
| 2010 | 9.72 | 218.69% |
| 2009 | 3.05 | |
| 2005 | 466 | 406.31% |
| 2004 | 92.0 | 202.3% |
| 2003 | 30.4 | 26.23% |
| 2002 | 24.1 | -32.43% |
| 2001 | 35.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 10.3 | -85.04% | 🇺🇸 USA |
 Novartis NVS | 24.8 | -64.21% | 🇨🇭 Switzerland |
 Pfizer PFE | 13.7 | -80.26% | 🇺🇸 USA |
 Merck MRK | 68.7 | -0.61% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 11.2 | -83.78% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -6.39 | -109.24% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.